Type I Interferon-Mediated Killing of Cancer Cells with IAP-Targeted Combination Immunotherapy

SMAC mimetic compounds (SMCs) are small molecule antagonists of the Inhibitor of Apoptosis (IAP) family of proteins. Binding of SMCs to the IAPs results in the sensitization of cancer cells to apoptosis in the presence of death ligands, such as tumour necrosis factor alpha (TNFα). I hypothesize that type I interferon (IFN) stimulation in cancer cells and in immune cells leads to the production of TNFα, which can then synergize with SMCs to kill cancer cells. The combined treatment of SMC and IFNα induces tumour regression in mice, and this effect is completely abrogated upon treatment with TNFα-neutralizing antibody. The synergistic effects are mediated by tumour cells and by contribution of immune cells, particularly macrophages and dendritic cells, as the systemic depletion of phagocytic innate immune cells results in an increase in tumour volume following combination treatment. The characterization of immune cell contribution will aid in the translation of the SMC combination therapy into clinical applications for the treatment of cancer.

Grantor dc:publisher

Université d'Ottawa / University of Ottawa

Year dc:date

2016

Author dc:creator

• Beauregard, Caroline

Contributors dc:contributor

• Korneluk, Robert

• Cancer
• Immunotherapy
• SMAC Mimetics
• Interferon

Language dc:language

en

Identifier

http://dx.doi.org/10.20381/ruor-5317

OAI identifier oai:identifier

oai:ruor.uottawa.ca:10393/34201